Physician profile
Jerome B Gabry
NPI 1356342117
$1,689.29
in general payments reported to CMS, 2019-2025
17 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $184 · 2021: $169 · 2022: $200 · 2023: $372 · 2024: $392 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $871.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $348.06 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Oyster Point Pharma, INC. | $215.74 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Alcon Vision LLC | $164.56 | 2020-2025 | Clareon Panoptix Pro, Eysuvis, Rocklatan |
| Aerie Pharmaceuticals, INC. | $164.02 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $140.00 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $122.05 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $115.51 | 2024 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $103.29 | 2019-2024 | Cequa |
| Dompe US, INC. | $65.62 | 2024 | Oxervate |
| Allergan, INC. | $55.20 | 2019-2022 | |
| Shire North American Group INC | $45.34 | 2019 | |
| Kala Pharmaceuticals, INC. | $40.63 | 2019-2021 | |
| Rxsight INC | $34.33 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Johnson & Johnson Vision Care, INC. | $23.64 | 2019-2020 | |
| Abbvie INC. | $22.58 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lensar, INC. | $17.49 | 2024 | Lensar Laser System |
| Eyevance Pharmaceuticals LLC | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerome Gabry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.